Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61,047 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial.
Liu X, Zhang X, Jiang S, Mo M, Wang Q, Wang Y, Zhou L, Hu S, Yang H, Hou Y, Chen Y, Lu X, Wang Y, Zhou X, Li W, Chang C, Yang X, Chen K, Cao J, Xu Q, Sun Y, Luo J, Luo Z, Hu X. Liu X, et al. Among authors: yang h, yang x. Lancet Oncol. 2024 Aug;25(8):1092-1102. doi: 10.1016/S1470-2045(24)00313-9. Epub 2024 Jul 25. Lancet Oncol. 2024. PMID: 39068945 Clinical Trial.
ERBB2 mutation: A promising target in non-squamous cervical cancer.
Xiang L, Jiang W, Ye S, He T, Pei X, Li J, Chan DW, Ngan HYS, Li F, Tao P, Shen X, Zhou X, Wu X, Yang G, Yang H. Xiang L, et al. Among authors: yang g, yang h. Gynecol Oncol. 2018 Feb;148(2):311-316. doi: 10.1016/j.ygyno.2017.12.023. Epub 2017 Dec 24. Gynecol Oncol. 2018. PMID: 29279289
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Shi T, et al. Among authors: yang h. Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8. Lancet Oncol. 2021. PMID: 33705695 Clinical Trial.
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.
Tian W, Ren Y, Lu J, Jing C, Zhang W, Li H, Wang T, Hou Z, Yang T, Zhu W, Zhang Y, Shan B, Yang H, Cheng X, Wang H. Tian W, et al. Among authors: yang t, yang h. BMC Med. 2024 Aug 26;22(1):344. doi: 10.1186/s12916-024-03564-z. BMC Med. 2024. PMID: 39183277 Free PMC article. Clinical Trial.
61,047 results
You have reached the last available page of results. Please see the User Guide for more information.